Indianapolis Depo Provera® Lawyer

Contact our office for a free, confidential case review with an Indianapolis Depo-Provera® lawsuit attorney.

If you have been diagnosed with a meningioma brain tumor after receiving Depo-Provera® or Depo-SubQ Provera 104® injections, you may have a product liability claim against the manufacturer. Thousands of women have filed federal lawsuits alleging that Pfizer failed to warn patients about the established link between long-term use of the contraceptive injection and intracranial meningioma tumors. Ward & Ward Personal Injury Lawyers are accepting Indianapolis, IN Depo-Provera® lawsuits include those who received a meningioma diagnosis after at least one year of Depo-Provera® use. Contact our office for a free consultation.

Depo-Provera® Lawsuits Indianapolis, IN

A Depo-Provera® lawsuit is a product liability claim filed against Pfizer. The core allegation is straightforward: the company knew or should have known that long-term use of the injectable contraceptive carried a risk of meningioma brain tumors, and it failed to update the product’s U.S. labeling to warn the women taking it or the physicians prescribing it.

The active ingredient is medroxyprogesterone acetate, a synthetic hormone that suppresses ovulation. Medical providers have administered Depo-Provera® to millions of women since its approval for contraceptive use. Published research over the past several years has demonstrated a statistically significant connection between prolonged use and elevated meningioma risk. Then, in December 2025, the FDA approved updated labeling that added a meningioma warning and recommended discontinuation if a tumor is diagnosed. The plaintiffs’ position in the federal litigation is that this warning arrived years too late.

Types of Depo-Provera® Cases We Handle in Indianapolis

Ward & Ward Personal Injury Lawyers represents clients in Indianapolis, IN and throughout Indiana across the following categories of Depo-Provera® claims:

• Meningioma after long-term use. Women who received Depo-Provera® injections for a year or longer and were later diagnosed with a meningioma make up the majority of the current federal litigation. At the center of every one of these claims is the same question: why did Pfizer not warn U.S. patients about this risk when the data was available?

• Meningioma requiring surgery. A craniotomy to remove a meningioma is a major procedure. The risks associated with opening the skull, the potential for surgical complications, and the weeks or months of recovery that follow all factor directly into the damages in these cases.

• Meningioma treated with radiation. Not every patient is a candidate for surgery. Others need radiation after surgery to address tumor cells that could not be removed. Radiation to the brain carries long-term risks of its own, and the compensation sought in these cases reflects that reality.

• Multiple meningioma tumors. Some Depo-Provera® users have developed more than one tumor. Multiple meningiomas complicate both treatment planning and the neurological outlook for the patient, and they often correlate with longer or higher-dose exposure to the drug.

• Wrongful death. When a meningioma causes or contributes to a patient’s death, surviving family members may bring a wrongful death claim against Pfizer in addition to or in place of the underlying product liability action.

• Claims involving Depo-SubQ Provera 104®. This formulation uses the same active ingredient as standard Depo-Provera® but is administered subcutaneously rather than intramuscularly. Women who used Depo-SubQ Provera 104® and developed meningioma tumors have claims on the same basis.

Why Choose Ward & Ward Personal Injury Lawyers for a Depo-Provera® Lawsuit in Indianapolis, IN?

Attorneys Prepared for Complex Product Liability Litigation

Donald W. Ward was admitted to the Indiana Bar in 1954. Over seven decades of plaintiff-side practice, he has handled injury and product liability matters at every level of complexity. He served as a Governor of the Association of Trial Lawyers of America, received the organization’s Service Award, and sat on the Character and Fitness Committee for the Indiana Board of Law Examiners. Charles P. Ward has practiced since 1989. He holds an AV Preeminent Peer Review Rating from Martindale-Hubbell, is recognized among the Top 25 Trial Lawyers by the Motor Vehicle Trial Lawyers Association, and has been listed in Who’s Who in America.

At Ward & Ward Personal Injury Lawyers, we have helped clients recover millions of dollars across a range of personal injury matters. We handle Depo-Provera® cases on a contingency fee basis. You pay no attorney fees unless our personal injury lawyer in Indianapolis, IN secures compensation for you.

What Is Important to Understand About a Depo-Provera® Case?

Damages, Liability, and Compensation for Depo-Provera® Cases

The legal theory in a Depo-Provera® case is failure to warn. Pfizer, the plaintiffs allege, placed a product into the market without disclosing a known risk of serious harm. That makes this a product liability action, and the damages reflect the severity of what a meningioma diagnosis means for the person who receives it.

Economic damages are the measurable costs. Economic damages are the measurable costs: brain surgery, radiation, hospitalization, follow-up imaging every few months, prescription medication, lost wages while recovering, and ongoing medical monitoring for recurrence. One craniotomy alone can produce medical bills well into six figures, and many patients need more than one round of treatment.

Non-economic damages cover what cannot be reduced to an invoice. Non-economic damages cover what cannot be reduced to an invoice, including pain from the surgery itself and the recovery that follows, cognitive effects caused by either the tumor or the procedures used to treat it, and the fear and anxiety that come with a brain tumor diagnosis. Permanent impairments that change the way a person works, parents, or moves through daily life.

The FDA’s prescribing information for Depo-Provera® now states that meningioma cases have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Indiana’s product liability statute of limitations under Indiana Code § 34-20-3-1 requires claims to be filed within two years of the date the cause of action accrues.

What Are Important Aspects of a Depo-Provera® Case?

This litigation moves differently than a standard personal injury claim. Several factors matter from the outset.

• Your Depo-Provera® use history needs to be documented. Pharmacy records, medical charts showing injection dates, and insurance claims all help establish how long you used the drug and at what intervals. Without this documentation, proving duration of exposure becomes significantly harder.

• The meningioma diagnosis itself must be confirmed through imaging, pathology, or surgical records. The type and location of the tumor, and whether it required surgery, radiation, or both, directly affect what the claim is worth.

• The federal litigation is structured as a multidistrict litigation. Individual cases from across the country are coordinated before a single federal judge in the Northern District of Florida. Your Indiana attorney works within that framework while protecting your individual interests.

• Pfizer has argued that federal preemption bars failure-to-warn claims because the manufacturer cannot unilaterally change product labeling without FDA approval. Plaintiffs have countered with evidence that Pfizer had data sufficient to support a stronger warning and failed to act on it.

• European regulators updated Depo-Provera® labels to warn about meningioma risk before the FDA acted on the U.S. label. That gap is a central piece of the plaintiffs’ argument. Pfizer had the information. The warning existed elsewhere. It was not applied here.

What Is the Depo-Provera® Case Timeline?

The litigation is still in pretrial phases. But the process of an individual case follows a sequence, even within that larger proceeding.

• Your attorney reviews medical records and Depo-Provera® usage history to determine whether you qualify for the litigation.

• A Plaintiff Proof of Use/Injury Questionnaire is submitted to the court, verifying drug use and the meningioma diagnosis.

• The case is filed. In federal court, it is transferred to the MDL for coordinated pretrial proceedings.

• General causation proceedings address whether Depo-Provera® is capable of causing meningioma. This phase involves depositions of medical and scientific professionals and Daubert hearings on the admissibility of that testimony.

• Bellwether trials are scheduled to begin in late 2026. These test cases will go before a jury and are expected to shape settlement negotiations across the rest of the litigation.

• Individual cases resolve through settlement, trust fund payments if any are established, or trial.

What Should You Bring to Your Depo-Provera® Consultation?

Organizing your records before the initial meeting allows the attorney to assess your claim more quickly. If you have access to the following, bring them:

• Medical records confirming the meningioma diagnosis, including imaging and pathology results

• Records of Depo-Provera® injections, including dates, prescribing physician, and pharmacy documentation

• Documentation of surgical procedures, radiation, or other treatment related to the tumor

• Records showing lost income or employment consequences tied to the diagnosis

• Insurance and benefits information

Your attorney will evaluate the facts, determine whether you qualify for the current litigation, and walk you through the next steps. This consultation is free and carries no obligation.

What Are Important Indiana Legal Resources for Depo-Provera® Cases?

Federal product liability law and the MDL procedural rules govern most aspects of a Depo-Provera® case, but Indiana state law applies as well. These resources offer a starting point:

• Indiana Code § 34-20-3-1 sets a two-year statute of limitations for product liability claims based on negligence or strict liability, running from the date the cause of action accrues.

• Indiana Code § 34-51-2-6 establishes Indiana’s modified comparative fault rule. If the claimant’s own fault exceeds 50 percent, recovery is barred.

• The FDA’s current prescribing information for Depo-Provera® includes the meningioma warning added in December 2025.

• The Indiana General Assembly website provides full access to the Indiana Code, including the product liability provisions in Title 34, Article 20.

• The FDA MedWatch program allows patients and healthcare professionals to report adverse events associated with pharmaceutical products, including Depo-Provera®.

Reach Out to Ward & Ward Personal Injury Lawyers to Schedule a Consultation

If you have been diagnosed with a meningioma brain tumor after using Depo-Provera® or Depo-SubQ Provera 104® in Indianapolis, IN, Ward & Ward Personal Injury Lawyers can evaluate your case and advise you on whether you qualify for the current federal litigation. We handle these cases on contingency. No upfront costs, and no attorney fees unless we recover compensation on your behalf. Contact us to schedule a free and confidential case review with a Depo-Provera® lawsuit attorney at Ward & Ward Personal Injury Lawyers.